26 min listen
Can Allegro’s Integrin Peptide Therapy Help Usher in Retina 2.0 for Vitreoretinal Indications?
Can Allegro’s Integrin Peptide Therapy Help Usher in Retina 2.0 for Vitreoretinal Indications?
ratings:
Length:
23 minutes
Released:
Jul 20, 2016
Format:
Podcast episode
Description
Allegro Ophthalmics’ executive team boasts a successful pedigree that began with starting ISTA and taking it public. Now, Vicken Karageozian, MD, president and CMO, says the company is six months away from receiving results from Phase II trials. Hear how the firm has advanced this promising new drug without venture capital.
Released:
Jul 20, 2016
Format:
Podcast episode
Titles in the series (100)
Blumenkranz Shares His Success, Failures And New Opportunities For Ophthalmic Innovators by OIS Podcast | Ophthalmology's leading Podcast